US · Healthcare · Biotechnology
EPS came in at 0.02 against a street estimate of -0.27 — a beat of 107.4%.
Analysts rate Omeros Corporation a buy (2 buy, 2 hold, 0 sell out of 4) with an average price target of $33.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.33% |
| Ingalls & Snyder LLC | 4.92% |
| Vanguard Capital Management, LLC | 4.12% |
| UBS Group AG | 3.23% |
| State Street Corp | 2.65% |
| Stifel Financial Corp | 2.53% |
| Geode Capital Management, LLC | 2.42% |
| Vanguard Portfolio Management, LLC | 0.99% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 OMEROS CORPORATION (OMER) - 8-K SUMMARY HEADLINE NUMBERS • Board size increased from 8 to 9 directors • New director granted stock option for 30,000 | 2026-08-13 |
| Quarterly report · Q2 2026 OMEROS CORPORATION - FORM 10-Q SUMMARY For Quarter Ended June 30, 2026 --- HEADLINE NUMBERS • Cash and Short-Term Investments: $131.95 million (Jun | 2026-08-12 |
| Results announced · Q3 2026 OMEROS CORPORATION Q2 2026 FINANCIAL SUMMARY HEADLINE NUMBERS • YARTEMLEA gross revenues: $32.2 million in Q2 2026, up 190% from $11.1 million in Q1 | 2026-08-12 |
| Company announcement · Q3 2026 OMEROS CORPORATION (OMER) — 8-K SUMMARY HEADLINE NUMBERS • Company repurchased $14.5 million aggregate principal amount of 9.50% Convertible Senior | 2026-07-20 |
| Company announcement · Q3 2026 OMEROS CORPORATION (OMER) - 8-K SUMMARY HEADLINE NUMBERS • Company repurchasing 9.50% Convertible Senior Notes due 2029 in two tranches • First tran | 2026-07-06 |
| Quarterly report · Q1 2026 OMEROS CORPORATION – Q1 2026 FORM 10-Q SUMMARY HEADLINE NUMBERS • Product sales (Q1 2026): $9.9 million (first commercial sales; zero in Q1 2025) • | 2026-05-13 |
| Proxy statement · Q2 2026 OMEROS CORPORATION 2026 PROXY SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class II directors (Thomas J. Cable, Peter A. Demopu | 2026-04-30 |
| Annual report FY2025 OMEROS CORPORATION – 10-K SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • FDA Approval Achieved: YARTEMLEA (narsoplimab) approved by FDA on December | 2026-03-31 |
Readable in the app.
| Announcement | Date |
|---|---|
| Closed asset sale transaction with Novo Nordisk for zaltenibart program Omeros Corporation reported strong fourth quarter 2025 results driven by a major licensing deal with Novo Nordisk. The company received a $240 million upfront payment for exclusive global ri | 2026-03-31 |
| FDA Approves YARTEMLA for TA-TMA Treatment in Adults and Children Omeros received FDA approval for YARTEMLEA (narsoplimab-wuug), the first and only approved treatment for TA-TMA (hematopoietic stem cell transplant-associated thrombotic microangiopathy), a | 2025-12-29 |
| Sold exclusive global rights to zaltenibart program to Novo Nordisk Omeros Corporation completed the sale of its lead drug candidate zaltenibart (OMS906) and related assets to Novo Nordisk on November 25, 2025. Omeros received $240 million upfront in cash, w | 2025-12-01 |
| Asset purchase and license agreement with Novo Nordisk for lead antibody candidate Omeros Corporation announced a major licensing deal with Novo Nordisk for its lead drug zaltenibart. Under the agreement, Omeros will receive $240 million upfront upon closing (expected Q4 2 | 2025-11-13 |
| Asset purchase and license agreement for clinical-stage MASP-3 inhibitor Novo Nordisk acquired global rights to zaltenibart (OMS906), an experimental antibody drug developed by Omeros for rare blood and kidney disorders. Omeros receives $340 million upfront plus | 2025-10-15 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Omeros Corporation — free to start.
Google PlayApp StoreData updated 2026-09-18.